A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group - PubMed (original) (raw)
Clinical Trial
. 1997 Dec 15;90(12):4710-8.
D Hoelzer, M A Sanz, K Lechner, J A Liu Yin, G Papa, L Noens, J Szer, A Ganser, C O'Brien, J Matcham, A Barge
Affiliations
- PMID: 9389686
Free article
Clinical Trial
A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group
G Heil et al. Blood. 1997.
Free article
Abstract
The safety and efficacy of filgrastim as an adjunct to acute myeloid leukemia (AML) induction and consolidation therapy was assessed in this prospective double-blind, randomized, placebo-controlled, multicenter trial. A total of 521 consecutive de novo AML patients aged 16 or more years were randomized to receive filgrastim (5 microg/kg/d subcutaneously) or placebo after standard induction as well as consolidation chemotherapy. Blinded study drug was given from 24 hours after chemotherapy until the absolute neutrophil count was >/=1.0 x 10(9)/L for 3 consecutive days. The overall complete remission rate was 68%. After a median follow-up of 24 months (range 5 to 40) the median disease-free survival was 10 months (95% confidence interval [CI], 8.7 to 10.8) and the median overall survival was 13 months (95%CI, 12.2 to 14.6). These did not differ between treatment groups. Patients receiving filgrastim experienced neutrophil recovery 5 days earlier after induction 1 than those receiving placebo (P < .0001). This was accompanied by reductions in the duration of fever (7 v 8.5 days; P = .009), parenteral antibiotic use (15 v 18.5 days; P = .0001), and hospitalization (20 v 25 days; P = .0001). Similar reductions were seen after induction 2 and the consolidation courses. There was a significant reduction in the number of patients requiring systemic antifungal therapy in the filgrastim group during induction treatment (34% v 43%; P = .04). In conclusion, filgrastim is safe in that it had no negative impact on the prognosis of the AML patients. In addition, it effectively reduced the duration of neutropenia, leading to significant clinical benefits by reducing the duration of fever; requirement for parenteral anti-infectives, specifically amphotericin B; and the duration of hospitalization.
Similar articles
- A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial.
Sierra J, Szer J, Kassis J, Herrmann R, Lazzarino M, Thomas X, Noga SJ, Baker N, Dansey R, Bosi A. Sierra J, et al. BMC Cancer. 2008 Jul 10;8:195. doi: 10.1186/1471-2407-8-195. BMC Cancer. 2008. PMID: 18616811 Free PMC article. Clinical Trial. - A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.
Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA. Larson RA, et al. Blood. 1998 Sep 1;92(5):1556-64. Blood. 1998. PMID: 9716583 Clinical Trial. - Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis.
Feng X, Lan H, Ruan Y, Li C. Feng X, et al. Hematology. 2018 Oct;23(9):581-589. doi: 10.1080/10245332.2018.1446811. Epub 2018 Mar 8. Hematology. 2018. PMID: 29516766 Review. - Granulocyte-colony stimulating factor in the prevention of postoperative infectious complications and sub-optimal recovery from operation in patients with colorectal cancer and increased preoperative risk (ASA 3 and 4). Protocol for a controlled clinical trial developed by consensus of an international study group. Part two: design of the study.
Bauhofer A, Lorenz W, Stinner B, Rothmund M, Koller M, Sitter H, Celik I, Farndon JR, Fingerhut A, Hay JM, Lefering R, Lorijn R, Nyström PO, Schäfer H, Schein M, Solomkin J, Troidl H, Volk HD, Wittmann DH, Wyatt J; Lucerne Group for Consensus-assisted Development of the Study Protocol on Prevention of Abdominal Sepsis: Example G-CSF. Bauhofer A, et al. Inflamm Res. 2001 Apr;50(4):187-205. doi: 10.1007/s000110050744. Inflamm Res. 2001. PMID: 11392607 Review.
Cited by
- Double Emergency: A Case of Concurrent Heparin-Induced Thrombocytopenia and Acute Promyelocytic Leukemia.
Schuldt A, Samour M. Schuldt A, et al. Cureus. 2024 Apr 24;16(4):e58927. doi: 10.7759/cureus.58927. eCollection 2024 Apr. Cureus. 2024. PMID: 38800206 Free PMC article. - Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Maeda T, Najima Y, Kamiyama Y, Nakao S, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Miumra Y, Endo M, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Yano S. Maeda T, et al. Int J Clin Oncol. 2024 May;29(5):535-544. doi: 10.1007/s10147-023-02465-0. Epub 2024 Mar 18. Int J Clin Oncol. 2024. PMID: 38494578 Free PMC article. - Efficacy and Safety of Filgrastim and Its Biosimilars to Prevent Febrile Neutropenia in Cancer Patients: A Prospective Study and Meta-Analysis.
Rastogi S, Kalaiselvan V, Ali S, Ahmad A, Guru SA, Sarwat M. Rastogi S, et al. Biology (Basel). 2021 Oct 19;10(10):1069. doi: 10.3390/biology10101069. Biology (Basel). 2021. PMID: 34681169 Free PMC article. - Comparison of Long-Acting G-CSF (PD-Lasta) with Short-Acting G-CSF (PD-Grastim) in Neutrophil Recovery Following Consolidation Chemotherapy with High-Dose Cytarabine in Acute Myeloid Leukemia: A Randomized Clinical Trial.
Esfandbod M, Agha Bararzadeh F, Faraz M, Zarrabi F, Toogeh G. Esfandbod M, et al. Int J Hematol Oncol Stem Cell Res. 2021 Apr 1;15(2):96-102. doi: 10.18502/ijhoscr.v15i2.6040. Int J Hematol Oncol Stem Cell Res. 2021. PMID: 34466208 Free PMC article. - Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia.
Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW, Ustun C, Andreadis C, Frankfurt O, Foran JM, Lister J, Schiller GJ, Wieduwilt MJ, Pagel JM, Stiff PJ, Liu D, Khan I, Stock W, Kambhampati S, Tallman MS, Morris L, Edwards J, Pusic I, Kantarjian HM, Mamelok R, Wong A, Van Syoc R, Kellerman L, Panuganti S, Mandalam R, Abboud CN, Ravandi F. Desai PM, et al. J Clin Oncol. 2021 Oct 10;39(29):3261-3272. doi: 10.1200/JCO.20.01739. Epub 2021 Jun 22. J Clin Oncol. 2021. PMID: 34156898 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical